Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Ultra-sensitive cell-free DNA (cfDNA) sequencing uncovers clonal hematopoiesis as a major source of somatic cfDNA variants in healthy individuals and patients with cancer, and underscores the importance of matched white blood cell DNA sequencing in liquid biopsy procedures.
Inhibition of CSF-1R with recurrent activating alterations and other actionable targets identified by genomic sequencing elicits clinical activity in patients with histiocytosis.
New findings regarding the risks of over-the-counter probiotics in critically ill patients underscore the need for microbiota-targeted therapies that are based on efficacy in a disease- and host-specific context.
Sergiu Pașca is a faculty member at Stanford University, where he is also the Uytengsu Director of the Stanford Brain Organogenesis Program. He is a pioneer in developing 3D brain-region-specific organoids, assembloids and cellular models of neuropsychiatric disease from stem cells.
Dapagliflozin, a sodium-glucose co-transporter-2 inhibitor, reduced the risk of cardiovascular death or heart failure events in 4,744 patients with chronic heart failure with reduced ejection fraction.
Cardiometabolic disease is the leading cause of death and disability in the world, driven in part by the rise in unhealthy diets, poor air quality and other byproducts of economic development. A new economic model is needed, one that places people rather than profits at its center.
The rise in cardiometabolic diseases is linked to the availability of unhealthy products from industry, such as ultraprocessed foods, and studying the efficacy of intervention strategies against these products must be high on the research agenda.
Sex differences in the prevalence, risk factors and symptoms of cardiometabolic disorders are being elucidated and should be taken into account in diagnosis and treatment.